DAPA-HF的适用性:从心脏病学环境的角度来看
Massimo Iacoviello1, Marco Marini2, Mauro Gori3
1Medical and Surgical Sciences Department, University of Foggia, Foggia, Italy.
Acta cardiologica
|August 22, 2023
概括
-葡萄糖共运输体2抑制剂 (SGLT2-i) 对心力衰竭 (HF) 患者显示有前途. 一项研究发现,73%的意大利心力衰竭患者的减排分数符合关键试验的资格标准.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- -葡萄糖携带载体2抑制剂 (SGLT2-i) 在减少心力衰竭 (HF) 住院,慢性病 (CKD) 进展和死亡率方面表现出有效性.
- 现实世界的数据对于了解超越临床试验人群的治疗概括性至关重要.
研究的目的:
- 在意大利心力衰竭网络 (IN-HF) 登记处评估心力衰竭患者的适用性,以减少排气分数 (HFrEF) 为DAPA-HF试验标准.
- 评估SGLT2抑制剂发现对当代HFrEF患者队列的适用性.
主要方法:
- 来自IN-HF注册表的3415名HFrEF患者的分析.
- 与DAPA-HF试验人群 (4744名患者) 患者特征的比较.
- 对DAPA-HF纳入标准的理论资格的评估.
主要成果:
- 3415名IN-HF患者与DAPA-HF参与者具有重叠的基线特征.
- 在IN-HF队列中,DAPA-HF标准的理论合格率为73%.
- 与DAPA-HF相比,IN-HF群体的2型糖尿病和缺血性心力衰竭病因发病率较低.
结论:
- 大多数在心脏病学环境中跟踪的当代HFrEF患者符合DAPA-HF等试验的资格标准.
- 研究结果表明,在临床试验中观察到的SGLT2抑制剂的益处可能可以将其推广到更广泛的HFrEF人群中.
- 这项研究为临床医生和政策制定者提供了关于在现实世界HFrEF管理中使用SGLT2抑制剂的宝贵见解.
相关概念视频
01:30Cardiomyopathy II: Dilated Cardiomyopathy
11
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
11
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
16
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
16
01:22Heart Failure VI: Adjunct Therapies
16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
01:29Cardiomyopathy V: Interprofessional Care
16
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:27Heart Failure I: Introduction
16
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
16